Novartis AG Reaches New 52-Week High at $90.95 (NVS)
Novartis AG (NYSE:NVS) reached a new 52-week high during mid-day trading on Thursday , Analyst Ratings Network.com reports. The company traded as high as $90.95 and last traded at $90.77, with a volume of 397,281 shares trading hands. The stock had previously closed at $90.40.
A number of research firms have recently commented on NVS. Analysts at Barclays upgraded shares of Novartis AG from an “underweight” rating to an “equal weight” rating in a research note on Monday, June 9th. Separately, analysts at Leerink Swann raised their price target on shares of Novartis AG from $93.00 to $104.00 in a research note on Wednesday, May 28th. They now have an “outperform” rating on the stock. Finally, analysts at Jefferies Group upgraded shares of Novartis AG from a “hold” rating to a “buy” rating in a research note on Friday, May 2nd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the stock. Novartis AG has an average rating of “Hold” and a consensus price target of $93.50.
The stock has a 50-day moving average of $89.02 and a 200-day moving average of $83.29. The company has a market cap of $222.3 billion and a price-to-earnings ratio of 23.06.
Novartis AG (NYSE:NVS) last posted its quarterly earnings results on Thursday, April 24th. The company reported $1.31 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.27 by $0.04. The company had revenue of $14.02 billion for the quarter, compared to the consensus estimate of $14.25 billion. During the same quarter in the prior year, the company posted $1.32 earnings per share. The company’s quarterly revenue was up .0% on a year-over-year basis. Analysts expect that Novartis AG will post $5.22 EPS for the current fiscal year.
Novartis AG provides healthcare solutions. The Company is a multinational group of companies specializing in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.